Nitrosamine impurities

Mérieux NutriSciences
Pharma & Healthcare | One-stop shop solution

Nitrosamine impurities analysis on APIs and drug products

Mérieux NutriSciences’ GMP Labs offers advanced solutions through a cutting-edge technology to guarantee the safety and conformity of your pharmaceutical products

On September 26th, 2019 the CMDh (Heads of Medicines Agencies) published the notice “Information on nitrosamines for marketing authorisation holders” asking to all Marketing Authorization Holders (MAHs) of human medicinal products containing chemically synthesised active pharmaceutical ingredients to evaluate the risk of the presence of nitrosamine impurities in their products.

Soon after, similar requirements have been extended rapidly and globally to other Countries, drug products (e.g. biological medicinal products) and new complex nitrosamines (NDSRIs) requiring high levels of expertise, technology and capacity in order to ensure product safety and mandatory deadlines.

Discover Our Value: Mérieux NutriSciences Highlights

60+

Developed methods for the analysis of NSDRIs

7

LC-MS/MS instruments for nitrosamines tests

12.000+

Tests on Pharmaceutical products and APIs

6

Several analytical techniques as GC-MS, LC-MS

25

Senior Experts & Technical Analysts

3

R&D, QC and in vitro genotox labs

15

Years of Experience

Mérieux NutriSciences Pharma Nitrosamines Labs Global Service 

Method development and validation, screening and confirmatory tests of small nitrosamines and NDSRIs in APIs and drug products.
Multiresidual Analysis

Multiresidual Analysis

NDMA, NDEA, NDELA, NMOR and many others

Targeted methods for almost 50 NDSRIs

Targeted methods for almost 50 NDSRIs

Expertise, capacity, and emergencies management

The GMP facility of Mérieux NutriSciences is equipped with a dedicated lab and all analytical techniques suitable for the detection of nitrosamine impurities in different products.

 

Acknowledgements & Authorizations

The risk evaluation process

RISK EVALUATION

MAHs should perform risk evaluation of their medicinal products containing chemically synthesised APIs.

CONFIRMATORY TESTING

Confirmatory tests should be carried out using validated and sensitive methods. MAHs should inform the competent authorities immediately if tests confirm the presence of a nitrosamine impurity irrespective of the amount detected.

CHANGES TO THE MARKETING AUTHORISATION

MAHs should apply for a variation in a timely manner to introduce any required changes, such as amendment of the manufacturing process or changes to product specifications.

Connect with us

Use the contact form to get in touch with us and download our brochure. Book an analysis test, request a personalised consultation or tell us your request: we're here to answer your questions and help you with your needs.

Questo sito è protetto da reCAPTCHA e Google politica sulla riservatezza E Termini di servizio fare domanda a.

MxNS | Pharma & Healthcare
One-stop shop solution

As valued partner to the global pharma industry, Mérieux NutriSciences | Pharma & Healthcare offers research, development and quality control testing.

From active ingredients to finished products, our Pharma GxP Labs - more than 20.000 sqm based in Italy - present a complete spectrum of analytical and research services that include safety and quality control, analytical methods development and validation, and bioanalytical testing.

Discover all MxNS testing services: quality controls - investigation studies - absorption studies - R&D and validation activities - stability & storage conditions - cleaning and disinfectants validation - environmental services for pharma facilities.